SOLICITATION NOTICE
A -- Assays of Biological Specimens for Division of Epidemiology, Statistical and Prevention Research (DESPR)
- Notice Date
- 4/5/2010
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute of Child Health and Human Development, Contracts Management Branch, 6100 Executive Blvd., Suite 7A07, MSC7510, Bethesda, Maryland, 20892-7510
- ZIP Code
- 20892-7510
- Solicitation Number
- RFP-NIH-NICHD-DESPR-2010-05
- Point of Contact
- Lynn L Salo, Phone: 301-435-6962, Elizabeth D Osinski, Phone: 301-435-6947
- E-Mail Address
-
ls59u@nih.gov, eo43m@nih.gov
(ls59u@nih.gov, eo43m@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH) intends to solicit proposals to award an IDIQ contract to an organization to provide assaying services for biological specimens collected from numerous NICHD research studies. The anticipated contract type will be cost reimbursement with fixed unit prices per assay with a five year period of performance. Further details will be provided in the Request for Proposals (RFP) to inform interested Offerors of an overview of the type of assaying to be performed. NICHD is looking for potential sources who can demonstrate and document experience in conducting the following assays that are anticipated: a) Reproductive hormones (including testosterone, estrone, estradiol, estriol, quantitative hCG, inhibin-A) in serum/plasma, urine and saliva; sex hormone binding globulin in serum/ plasma; b) Phytoestrogens, including Genistein, Daidzein, o-Desmethylangolensin, Enterodiol, and Enterolactone, in urine; c) Stress hormones (including cortisol, ACTH, CRH, alpha-amylase) in serum/plasma, urine and/or saliva; d) Protein hormones (including parathyroid hormone, insulin, C-peptide, prolactin, IGF1, IGF-2, IGFBP-2) in serum/plasma and urine, as appropriate; e) Targeted and global metabolomics in serum or plasma; f) Proteomic analysis of semen, serum and urine; g) Enzymatic (glucokinase) assay for 1,5-anhydroglucitol (1,5-AG) in whole blood; h) Angiogenesis-related compounds (including placental growth factor, soluble endoglin, soluble vascular endothelial growth factor receptior-1 (sFlt-1)) in serum; placental growth factor in urine; i) Nutritional biomarkers (including alpha- and beta-carotene, lycopene, zeaxanthin plus lutein, retinol, retinol binding protein 4, beta-cryptoxanthin, 25 hydroxy-vitamin D, ferritin, transferrin receptor) in serum/plasma; j) Urinary 8-iso-prostaglandin F2 and microalbumin; k) Cytokines and inflammatory markers (including, but not limited to TNF-alpha, IL1-beta, IL-6, IL-8 and high-sensitivity CRP) in serum, urine and cervical or vaginal fluid as appropriate; l) Adipokines and related substances (including soluble leptin receptor, leptin, resistin, adiponectin, HMW-adiponectin, visfatin, incretin, GLP-1, ghrelin) in serum/plasma; m) Cotinine in plasma/serum, urine, hair or other matrices as specified; n) Amplification, high-throughput sequencing, genus/species identification and phylogenetic analysis of DNA for bacterial 16 S ribosomes and/or chaperonin-60 in vaginal wash specimens, and in gingival crevicular fluid preserved in filter paper and frozen; o) SNP genotyping of previously collected and prepared DNA samples; p) Extraction and amplification of DNA from salivary samples; identification of polymorphisms in genes (to be specified) relating to obesity, diet, physical activity, substance use, and aggression; q) Conduct of small (n=20) genome-wide association studies of children with rare syndromes. Analysis to include polymorphisms of copy number variants. DNA will have been previously extracted and amplified; r) DNA methylation in 20 candidate genes and global methylation, including DNA extraction from buffy coat; s) Global gene expression including RNA extraction; t) Bisphenol-A and metabolites; phthalates and metabolites, in urine; u) Polychlorinated biphenyl congeners in serum; v) Organochlorine pesticides (including hexachlorobenzene, gamma-HCH, beta-HCH, oxychlordane, trans-nonachlor, trans-chlordane, cis-chlordane, cis-nonachlor, para, para-prime-DDT, para, para-prime-DDE, para, para-prime-DDD, ortho, para prme-DDT, mirex) in serum; w) PBDE congeners (including numbers 18, 47, 99, 100, 153, 154, and 209) in serum; x) Perfluorinated compounds (including PFOS, PFOA, PFOSA, PFHxS, PFHpA, PFNA, PFDA, PFUnDA, and PFDoDA) in serum; y) Complete urine panel of metals (arsenic (As), barium (Ba), beryllium e), cadmium (Cd), cobalt (Co), chromium (Cr), cesium (Cs), copper (Cu), manganese (Mn), lybdenum (Mo), nickel (Ni), lead (Pb), platinum (Pt), antimony (Sb), tin (Sn), tellurium (Te), llium (TI), uranium (U), vanadium (V),tungsten (W), and zinc (Zn). The RFP is anticipated to be posted on or about April 17, 2010 on FedBizOpps (FBO) website: http://www.fedbizopps.gov.The due date for submission of proposals in response to the RFP is anticipated to be on or about June 4, 2010. Information in the anticipated RFP supersedes any information in this pre-solicitation announcement. This acquisition has been designated as full and open competition under the North American Industry Classification System (NAICS) code 541380. Any questions concerning this announcement must be submitted in writing to Lynn Salo at ls59u@nih.gov, Contracting Officer or Elizabeth Osinski, Contracting Officer, at eo43m@nih.gov, or addressed to, NICHD Contracts Management Branch, Office of Acquisitions, NIDDK, NIH, 6100 Executive Boulevard, Room 7A-07, MSC 7510, Bethesda, Maryland 20892-7510 (if hand-delivered or sending by delivery service--6100 Executive Boulevard, Suite 7A-07, Rockville, Maryland 20852). No collect calls will be accepted. This is not an RFP and this announcement does not commit the Government to award a contract. The reference number to be used for this announcement is: RFP NIH-NICHD-DESPR-2010-05. All correspondence must cite the reference number as provided.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NICHD/RFP-NIH-NICHD-DESPR-2010-05/listing.html)
- Record
- SN02112911-W 20100407/100405234955-54defbfe53399020bf1dd59cdbe954af (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |